Serum doxofylline concentrations were evaluated after solid-phase extraction byhigh-performance liquid chromatography following administration of 100 mg doxofylline given as a single intravenous dose over 10 min or 400 mg doxofylline given orally twice daily for 5 days in six and eight non-smoking, fasting, chronic bronchitic patients, respectively. Doxofylline possessed a very short distribution phase following intravenous administration, with a sustained elimination phase (half-life 1.83 ± 0.37 h). After oral administration, the peak serum doxofylline concentration was 15.21 ± 1.73 μg/ml and the mean elimination half-life was 7.01 ± 0.80 h; there was a large inter-subject variability. No side-effects were experienced by the patients during the study.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Oral and intravenous pharmacokinetic profiles of doxofylline in patients with chronic bronchitis|
|Data di pubblicazione:||1990|
|Citazione:||Oral and intravenous pharmacokinetic profiles of doxofylline in patients with chronic bronchitis / E., Bologna; Lagana', Aldo; D., Terracino; P., Bolignari; P., Biffignandi. - In: JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. - ISSN 0300-0605. - STAMPA. - 18:4(1990), pp. 282-288.|
|Appartiene alla tipologia:||01a Articolo in rivista|